DealZone

M & A wrap: Roche goes hostile for gene firm Illumina

January 25, 2012

Roche is offering $5.7 billion in cash to buy U.S. gene sequencing company Illumina Inc in an unfriendly takeover bid that marks a major play by the Swiss drugmaker into the gene technology field.

AMR Corp, the bankrupt parent of American Airlines, is the prize in a likely bidding war by rival carriers, but any merger involving the third largest U.S. airline is expected to come on its own terms and timing, Soyoung Kim and Kyle Peterson write.

Morgan Stanley’s tech team is going after a big prize — the chance to lead the much-anticipated Facebook IPO that is expected to raise $10 billion, The Wall Street Journal reports.

Hedge funds that in the last month or so have purchased an estimated $5.2 billion of beaten down Greek bonds that mature on March 20 are now trying to unload their positions, DealBook says.

The Deal Professor takes a look at efforts to study the value of private equity.

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/